ClinicalTrials.gg
RecruitingNCT06488313Updated Mar 17, 2025

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

A Phase 2 interventional study of ARCT-810 in OTC Deficiency, Ornithine Transcarbamylase Deficiency and OTCD, sponsored by Arcturus Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Arcturus Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States — 6 open to participants now, 11 under way, 2 of them phase 3. Ornithine Carbamoyltransferase Deficiency Disease · United States.

Planned enrollment
9th of 12
9 · median 15
Started
2024
with 2 others
Phase 2
4 of 28
1 open now
Primary completion
2026-06
later than 0 of 10 live
Registered
27th of 28
by date
Lead sponsor
2 of 28
Arcturus Therapeutics, Inc.

Among the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 2, reaches primary completion later than 0 of the 10 other live ones, and was the 27th registered.

Ornithine Carbamoyltransferase Deficiency Disease

59 studies on the registry are indexed under Ornithine Carbamoyltransferase Deficiency Disease; 13 are open to participants now.

Browse Ornithine Carbamoyltransferase Deficiency Disease studies →

Open to participants now

6 of the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Ornithine Carbamoyltransferase Deficiency Disease studies recruiting now, 3 (30%) set no upper age limit and 6 (60%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, or all of them as a file.
02

Study summary

Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.

Read the detailed description

This a Phase 2a, open-label study of ARCT-810 in participants 12 years of age and older living with OTC deficiency. After a diet stabilization period of at least 4 weeks, all participants will be enrolled to receive ARCT-810 every two weeks, for up to five doses, at one of three dose levels. Clinic visits will occur during screening and at Days 1, 15, 29, 36, 43, 57, 60, 71, and 85. During the study, participants will remain on their current clinical management for OTC deficiency. Dose escalation or cohort expansion may occur following completion of three participants at each dose level.

03

Conditions studied

  • OTC Deficiency
  • Ornithine Transcarbamylase Deficiency
  • OTCD
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness and ability to comply with all the protocol requirements, complete all study visits and sign .
  2. Males and Females aged ≥12 years, at Screening.
  3. Documented clinical diagnosis of OTC deficiency.
  4. History of symptomatic hyperammonemia or elevated plasma ammonia or glutamine with clinical stability for at least 1 month prior to Screening.
  5. Medically managed for OTC deficiency and receiving a stable protein-restricted diet, dietary supplements, and/or ammonia scavenger regimen (if applicable) for at least 28 days.
  6. Good general health with no abnormal findings that would interfere with study procedures (including plasma ammonia within participant's historical range).
  7. Must be willing to adhere to guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled hypertension.
  2. Symptoms of infection for at least 7 days prior to dosing.
  3. within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
  4. History of any OTC gene therapy, or history of liver-derived stem cell therapy in the past 2 years.
  5. History of any organ transplant.
  6. History of severe allergic reaction to a liposomal or PEG-containing product.
  7. History of congenital or acquired cardiac disorders.
  8. Abuse of medications, illicit drugs or alcohol.
  9. Blood donation of 50 to 499 mL within 30 days of screening or of >499 mL within 60 days of screening.
  10. laboratory abnormalities on screening labs including >1.5, \< 60 mL/min/1.73m2 or positive test results for , , or .
  11. Inadequately controlled diabetes.
  12. Clinically significant anemia.
  13. Changes in maintenance therapies for OTC deficiency with 28 days prior to dosing.
  14. Medical history requiring continuous or intermittent systemic administration.
  15. Receipt of inhibitors of urea synthesis or drugs that significantly affect renal clearance.
  16. Recent treatment with another drug, biological agent, or device.
  17. Treatment with any oligonucleotide (siRNA or mRNA) within 6 months prior to screening. COVID-19 vaccines are not exclusionary.
  18. Involved in study conduct or an immediate family member of an individual involved in the study.
  19. Participated in another dosing cohort of the study.
  20. Any other conditions, in the opinion of the investigator, that would interfere with participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    ARCT-810

    Participants will receive up to 5 IV infusions of ARCT-810 administered at 14-day intervals.

    Biological: ARCT-810

Interventions

  • BiologicalARCT-810

    ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).

06

What researchers measure

Primary outcomes

  1. Incidence, severity and dose-relationship of adverse events (AEs)

    Safety and tolerability of ARCT-810 assessed by incidence, severity, and dose-relationship of AEs

    Time frame: Day 85

Secondary outcomes

  1. Stable isotope ureagenesis assay values (AUC of first isotope)

    Change from Baseline in stable isotope ureagenesis assay values (AUC of first isotope) following multiple doses of ARCT-810

    Time frame: Up to Day 85

  2. Stable isotope ureagenesis assay values (AUC of second isotope)

    Change from Baseline in stable isotope ureagenesis assay values (AUC of second isotope) following mulitple doses of ARCT-810

    Time frame: Up to Day 85

  3. Fasting plasma ammonia

    Proportion of participants maintaining normal morning fasting plasma ammonia

    Time frame: Up to Day 85

  4. Plasma Glutamine

    Change from Baseline in plasma glutamine and labeled glutamine as available

    Time frame: Up to Day 85

  5. Plasma pharmacokinetics

    The noncompartmental plasma pharmacokinetics of ARCT-810 will be assessed based on the observed plasma concentration of ARCT-810 mRNA and lipid

    Time frame: Up to Day 57

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jun 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 5, 2024
StartActual
Nov 4, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06488313
Lead sponsor
Arcturus Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Nov 4, 2024
Primary completion
Jun 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Mar 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARCT-810

Start the discussion